Genotype and dose-frequency may critically determine the therapeutic efficacy of chronic oxytocin treatment in humans

Authors: Juan Kou¹, Yingying Zhang¹, Feng Zhou¹, Cornelia Sindermann², Christian Montag², Benjamin Becker¹, Keith M Kendrick¹*

Affiliations:

¹The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu 611731, China.

²Department of Molecular Psychology, Institute of Psychology and Education, Ulm University, Ulm, Germany.

*Corresponding author: Keith M. Kendrick

Institute: The Clinical Hospital of Chengdu Brain Science, MOE Key Laboratory for NeuroInformation

University: University of Electronic Science and Technology of China,

Street Name & Number: No. 2006, Xiyuan Ave, West Hi-tech Zone, Chengdu, 611731, China.

Tel: 86-28-83201358. Fax: 86-28-83201358.

E-mail: kkendrick@uestc.edu.cn
Abstract

Chronic intranasal oxytocin administration daily is increasingly proposed as a therapy for social dysfunction but some clinical trials have reported small or no beneficial outcomes. No empirical evidence proves that this is optimal therapeutically or whether oxytocin receptor genotype influences treatment sensitivity. In a randomized, placebo-controlled pre-registered trial on 138 adult male subjects we investigated effects of single and repeated oxytocin treatment (24IU daily or alternatively days for 5 days). Primary neural outcomes assessed core therapeutic mechanisms of action, i.e. amygdala fear reactivity and amygdala-prefrontal intrinsic functional connectivity and modulation by oxytocin receptor polymorphisms (rs53576, rs2254298). The expected oxytocin-induced reduction in amygdala fear reactivity and associated anxious-arousal following single-dose administration was abolished after daily treatment but maintained when administered every other day. Oxytocin selectively reduced amygdala and arousal fear reactivity in AA homozygotes of rs53576 and A+ carriers of rs2254298. By contrast, oxytocin-enhanced intrinsic amygdala-prefrontal coupling was maintained independent of dose frequency and genotype. Together the findings provide the first evidence that infrequent rather than daily oxytocin administration protocols may be therapeutically most efficient and that its neural and behavioral anxiolytic actions are highly genotype-dependent.
**Introduction**

Intranasal oxytocin (OT) has been proposed as novel treatment to attenuate social dysfunctions and anxiety in autism spectrum disorder, social anxiety and schizophrenia (Kendrick et al., 2017; Meyer-Lindenberg et al., 2011; Young and Barrett, 2015) as well as an augmentative strategy to facilitate fear extinction (Eckstein et al., 2015) and working memory performance (Zhao et al., 2018).

Preclinical studies consistently suggest that effects on amygdala functioning (attenuated fear reactivity, increased amygdala-prefrontal intrinsic connectivity, (Eckstein et al., 2015; Meyer-Lindenberg et al., 2011) represent the primary therapeutic-relevant neural mechanism of action of intranasal OT. The proposed neural mechanisms have been validated using single dose administration protocols (with 24 International Units (IU) being established as optimal (Spengler et al., 2017)), however, in contrast initial clinical trials with chronic (twice daily) administration protocols over longer intervals reported inconsistent, or at best modest therapeutic efficacy on social-emotional dysfunctions (Guastella et al., 2015; Halverson et al., 2019; Jarskog et al., 2017; Kendrick et al., 2017; Watanabe et al., 2015; Yamasue et al., 2018).

G-protein-coupled neuropeptide receptors typically exhibit internalization following even a relatively short period of constant exposure to their target peptides and cannot subsequently respond (desensitized) until they are recycled back the surface of the cell membrane (Pierce et al., 2002; Lohse and Hofmann, 2015). Indeed,
neuroendocrine neurons in the hypothalamus regulating pituitary peptide release tend
to exhibit phasic discharge patterns resulting in a pulsatile pattern of release which
may serve to reduce internalization of their target receptors (Russell, 2018). Growing
evidence from both in vitro and animal studies suggest there may be extensive
internalization and subsequent desensitization of OT receptors (OXTR) following
chronic OT administration (Smith et al., 2006; Stoop, 2012). In terms of neural OXTR
receptors those in the amygdala may be particularly susceptible to desensitization
(Terenzi and Ingram, 2005) and this region critically mediates many of the effects of
intranasal OT on social cognition and anxiety (Kendrick et al., 2017). Moreover,
rodent models have reported that in contrast to single doses, chronic administration of
OT can actually produce social impairment (Bales et al., 2013; Du et al., 2017; Huang
et al., 2014) in the context of reduced receptor expression in the amygdala and
nucleus accumbens (Du et al., 2017). Furthermore, an initial study reported that
chronic versus single administration of OT results in divergent neurochemical
changes in both the rodent and human frontal cortex (Benner et al., 2018),
emphasizing high translational relevance of the preclinical animal models for clinical
trials employing chronic treatment protocols. Thus, empirically evaluated optimal
treatment protocols for chronic intranasal OT administration in humans are urgently
needed to determine the therapeutic potential of OT for social-emotional dysfunctions
in psychiatric disorders.
A further unresolved issue which may impede the therapeutic efficacy of intranasal OT is that different OT receptor (OXTR) genotypes have been associated with social behaviors and may also influence sensitivity of behavioral and neural responses to intranasal OT. In particular, OXTR polymorphisms rs53576 and rs2254298 have been associated with autism (Cataldo et al., 2018) and deficits in social and emotional processing and anxiety (Jurek and Neumann, 2018; Parker et al., 2014; Yang et al., 2017) as well as individual variations in behavioral and neural responses to intranasal OT (Chen et al., 2015; Feng et al., 2015a). Indeed, variants of rs2254298 may represent a trans-diagnostic biomarker for social dysfunctions (Brüne, 2012). It is therefore imperative to establish whether OXTR polymorphisms critically determine sensitivity to the key neural mechanisms of intranasal OT in order to identify treatment-responsive individuals likely to exhibit therapeutic benefits.

Although single doses of OT have been reported to produce numerous functional effects, those on amygdala functioning have been most consistently determined as promising key neural mechanisms: attenuated amygdala fear responses and increased resting state functional connectivity between the amygdala and medial prefrontal cortex (Kendrick et al., 2017; Spengler et al., 2017). Both neural markers have been primarily associated with attenuated anxiety in terms of reduced responses to social threat and enhanced top-down control of emotion (Zhao et al., 2019), although OT effects on the amygdala may also mediate its actions on a range of social cognition
domains (Kendrick et al., 2017; Meyer-Lindenberg et al., 2011; Spengler et al., 2017; Young and Barrett, 2015).

In order to determine optimal treatment protocols for chronic intranasal OT administration the current pre-registered double-blind, randomized between subject placebo (PLC)-controlled pharmacological neuroimaging trial (see Fig. 1) in 138 adult male subjects therefore aimed at determining the effects of acute (single dose) and repeated doses (daily or every other day for 5 days) of 24IU OT versus PLC on amygdala-centered neural and behavioral (valence, arousal and intensity ratings of fear faces) mechanisms of OT. To identify individuals with the most promising treatment sensitivity we additionally assessed the influence of OXTR rs53576 and rs2254298 polymorphisms on acute and repeated dose OT effects.

Results

Acute effects of OT on neural responses to emotional faces

In accordance with the primary outcome measure of the trial analyses focused on the neural responses to fearful faces, however no significant effects of OT were found for happy or angry faces. Comparison of single-dose OT- (combined OT3 and OT5 groups) and PLC-treated subjects (1st day) revealed significantly decreased right amygdala reactivity towards fearful faces on the whole brain level (k = 78, pFWE = 0.043, x=27, y=-4, z=-13) (Fig.2A). Cytoarchitectonic probabilistic localization (Anatomy toolbox V1.8 (Eickhoff et al., 2005)) mapped the peak coordinate with >80% probability to the basolateral amygdala sub-region. In addition, OT also decreased fear-reactivity in
the right superior frontal gyrus and bilateral primary visual cortex (see SI and Table S1). There were no significant differences between the OT₃ and OT₅ groups on the 1ˢᵗ day.

**Primary outcome measures: effects of repeated doses on OT-evoked changes**

Mixed ANOVAs with treatment (PLC, OT₃, OT₅) and time point (1ˢᵗ day, acute effects; 5ᵗʰ day, chronic effects) as factors and right amygdala fear reactivity as dependent variable revealed a significant main effect of treatment ($F_{2, 135} = 7.85$, $p = 0.001$, $\eta^2_p = 0.104$) and a treatment x time point interaction ($F_{2, 135} = 5.74$, $p = 0.004$, $\eta^2_p = 0.078$). Post-hoc Bonferroni corrected comparisons between groups on the 5ᵗʰ day revealed that the OT₃ group exhibited a suppression of right amygdala fear reactivity relative to both the PLC ($p = 0.001$, Cohen’s $d = 0.70$, 95% CI, -0.833 to -0.224) and OT₅ groups ($p = 0.018$, $d = 0.52$, 95% CI, -0.662 to -0.062) but the OT₅ group did not ($p = 0.266$, relative to the PLC group). Within group comparisons showed that whereas amygdala reactivity did not change on day 1 relative to day 5 in the PLC group ($p = 0.090$, $d = 0.29$, 95% CI, -0.035 to 0.487), its suppression was significantly enhanced in the OT₃ group ($p = 0.019$, $d = 0.40$, 95% CI, 0.054 to 0.595) and attenuated in the OT₅ one ($p = 0.044$, $d = 0.38$, 95% CI, -0.514 to -0.007) (Fig. 2B).

For the behavioral ratings mixed ANOVAs with treatment and time point as within-subject factors revealed a significant main effect of treatment for arousal, but
not intensity ratings (arousal: $F_{1, 135} = 4.99$, $p = 0.008$, $\eta^2_p = 0.07$, intensity: $F_{1, 135} = 2.60$, $p = 0.078$, $\eta^2_p = 0.04$), and time point for both emotional arousal and intensity ratings (arousal: $F_{1, 135} = 12.09$, $p = 0.001$, $\eta^2_p = 0.082$, intensity: $F_{1, 135} = 10.81$, $p = 0.001$, $\eta^2_p = 0.04$) although no significant two-way interactions (arousal: $F_{1, 135} = 1.85$, $p = 0.162$, $\eta^2_p = 0.03$, intensity: $F_{1, 135} = 2.97$, $p = 0.055$, $\eta^2_p = 0.04$). An exploratory post hoc analysis showed that both emotional arousal and intensity ratings for fear faces in the OT\textsubscript{3} group were decreased on the 5\textsuperscript{th} day (arousal: $p = 0.001$ versus PLC, $d = 0.63$, 95% CI, -1.544 to -0.420, $p = 0.033$ versus OT\textsubscript{5}, $d = 0.42$, 95% CI, -1.158 to -0.051; intensity: $p = 0.004$ versus PLC, 95% CI, -1.299 to -0.247, $d = 0.87$, $p = 0.088$ versus OT\textsubscript{5}, $d = 0.35$, 95% CI, -0.968 to 0.068). Although there was a significant decrease in arousal ratings in the OT\textsubscript{3} group on the 1\textsuperscript{st} day compared to the PLC group there was no difference between the OT\textsubscript{3} and OT\textsubscript{5} groups (arousal: $p = 0.015$ versus PLC, $d = 0.31$, 95% CI, 0.129 to 1.175, $p = 0.355$ versus OT\textsubscript{5}, 95% CI, -0.268 to 0.744). If we combined the two OT groups on the 1\textsuperscript{st} day to increase statistical power there was a marginal effect of decreased arousal but not intensity ratings (arousal: $p = 0.060$ versus PLC, $d=0.35$; intensity $p = 0.150$) (Fig.3). No significant main effects or interactions were found for valence ratings (all $p$s > 0.120).

Although not included in our primary outcome measures the (calcarine) visual cortex showed the same reduced responsivity to daily OT as the amygdala, and a similar pattern of association with behavioral intensity and arousal ratings, whereas the superior frontal gyrus did not (see SI). Voxel based morphometry analysis
revealed no evidence for acute or repeated dose effects of OT on gray matter volume

(see SI).

**Associations between amygdala responses and behavioral ratings to fear faces**

Significant associations between right amygdala activation and emotional arousal and intensity scores were observed in the PLC group on the 1\textsuperscript{st} day (arousal: $r = 0.44$, $p = 0.003$; intensity: $r = 0.54$, $p < 0.001$) demonstrating that greater amygdala activation by fear faces was associated with increased anxiety. This association was absent in both OT groups and significantly different from the PLC group on the 1\textsuperscript{st} day (arousal: OT\textsubscript{3}, $r = -0.21$, $p = 0.181$; Fisher’s $z = 3.08$, $p = 0.002$; OT\textsubscript{5}, $r = 0.09$, $p = 0.555$; $z = 1.79$, $p = 0.073$; intensity: OT\textsubscript{3}, $r = -0.13$, $p = 0.399$; Fisher’s $z = 3.33$, $p < 0.001$; OT\textsubscript{5}, $r = 0.12$, $p = 0.413$; $z = 2.35$, $p = 0.024$). The same effect was also seen on the 5\textsuperscript{th} day for arousal ratings (PLC: $r = 0.33$, $p = 0.024$; OT\textsubscript{3}, $r = -0.21$, $p = 0.187$; $z = 2.52$, $p = 0.012$; OT\textsubscript{5} group, $r = -0.15$, $p = 0.317$; $z = 2.33$, $p = 0.020$) although slightly weaker for intensity ratings (PLC: $r = 0.25$, $p = 0.092$; OT\textsubscript{3}, $r = -0.29$, $p = 0.057$; $z = 2.53$, $p = 0.011$; OT\textsubscript{5} group, $r = -0.03$, $p = 0.847$; $z = 1.34$, $p = 0.180$) (Fig.4).

**Effects of repeated oxytocin doses on resting-state functional connectivity**

Right-amygdala seed-to-whole brain fMRI resting-state analysis by mixed-effect ANOVA revealed a main effect of treatment (OT\textsubscript{3}, OT\textsubscript{5} and PLC) on amygdala functional coupling with vmPFC (peak MNI $x = -3$, $y = 53$, $z = -19$, $F_{2,135} = 16.55$, $p_{FWE} = 0.001$, $k = 88$) before subjects underwent the face paradigm, whereas no brain regions showed a significant time point x treatment interaction. Post-hoc analyses
demonstrated that right amygdala intrinsic connectivity with the vmPFC was stronger in both the OT$_3$ (k = 74, $p_{FWE} = 0.014$, $x = -3, y = 53, z = -19$) and OT$_5$ groups (k = 127, $p_{FWE} = 0.001$, $x = -3, y = 53, z = -19$) relative to PLC. Subsequent confirmatory analyses of resting state functional connectivity in this pathway acquired after the face task paradigm also revealed a significant main effect of treatment ($F_{2, 135} = 7.08$, $p = 0.001$, $\eta^2_p = 0.095$). Post hoc comparisons showed both groups exhibited increased connectivity in this pathway after a single OT dose on the 1$^{st}$ day (OT$_3$, $p = 0.001$, $d = 0.71$; OT$_5$, $p = 0.063$, $d = 0.40$; relative to PLC) and after repeated doses on the 5$^{th}$ day (OT$_3$ $p = 0.047$, $d = 0.46$; OT$_5$, $p = 0.001$, $d = 0.69$; relative to PLC). The OT$_3$ and OT$_5$ groups did not differ significantly on the 1$^{st}$ ($p = 0.140$) or 5$^{th}$ ($p = 0.208$) day (Fig. 5B).

**Associations with OXTR genotype**

The number of G-carriers and G-non-carriers of rs53576 as well as A-carriers and A-non-carriers of rs2254298 did not differ between the three groups and both SNPs satisfied the Hardy Weinberg Equilibrium (see Tables S2 and S3). With Bonferroni-correction for the multiple SNPs and alleles (i.e. $2 \times 2 = 4$), $p < 0.0125$ was considered significant. For amygdala responses there was a significant treatment x genotype interaction for rs53576 ($F_{2, 105} = 6.01$, $p = 0.003$, $\eta^2_p = 0.10$). Post-hoc analysis revealed that OT-induced amygdala suppression on the 1$^{st}$ day was only significant in G-non-carriers ($p < 0.001, d = 0.99$, 95% CI, 0.432 to 1.333) and also on the 5$^{th}$ day in the OT$_3$ group ($p < 0.001, d = 1.41$, 95% CI, 0.638 to 1.483). While the
interaction between treatment and genotype did not achieve significance for

rs2254298 ($F_{2, 105}= 1.48, p = 0.232, \eta^2_p = 0.03$) an exploratory post hoc analysis revealed that OT-induced suppression on the 1st day across treatment groups (OT$_3$ and OT$_5$ groups combined to increase power) was only significant in A-carriers ($p = 0.001$, $d = 0.91$, 95% CI, 0.337 to 1.244) and also on the 5th day in the OT$_3$ group ($p = 0.004$, $d = 0.81$, 95% CI, 0.218 to 1.122) (see Fig. 6). Similar patterns of genotype association were found for the visual cortex but not superior frontal gyrus responses to fear faces (see SI).

For both arousal and intensity ratings there was a significant treatment x genotype interaction for rs2254298 (arousal: $F_{2, 105} = 9.70, p < 0.001, \eta^2_p = 0.16$, intensity: $F_{2, 105} = 7.42, p = 0.001, \eta^2_p = 0.12$). To increase the statistical power, we combined the OT$_3$ and OT$_5$ groups on the 1st day. Post hoc analysis showed a significant decrease in ratings on the 1st day in the OT group only in A-carriers ($p = 0.014$ versus PLC, $d = 0.64$, 95% CI, 0.177 to 1.542; intensity: $p = 0.024$ versus PLC, $d = 0.60$, 95% CI, 0.109 to 1.478). There was a significant decrease in ratings on the 5th day in the OT$_3$ group only in A-carriers (arousal: $p < 0.001$ versus PLC, $d = 1.69$, 95% CI, -2.780 to -1.231; $p < 0.001$ versus OT$_5$, $d = 1.10$, 95% CI, -2.414 to -0.865; intensity: $p < 0.001$ versus PLC, $d = 1.56$, 95% CI, -2.531 to -1.075; $p = 0.001$ versus OT$_5$, $d = 0.97$, 95% CI, -1.993 to -0.536). There was also a significant difference between the 1st and 5th days in the OT$_3$ group only in A-carriers (arousal: $p=0.002$, $d =1.72$, 95% CI, 0.201 to 0.862, intensity: $p<0.001$, $d=0.42$, 95% CI, 0.272 to 0.914) not the other two
groups (ps > 0.06) and there was a significant difference between A-carriers and A-non carriers in the OT3 group (arousal: p=0.001, d =1.07, 95% CI, 0.578 to 2.172, intensity: p=0.001, d =1.01, 95% CI, 0.483 to 1.982) and in PLC group (arousal: p=0.032, d =0.92, 95% CI, -1.783 to -0.084, intensity: p=0.021, d = 0.88, 95% CI, -1.742 to -0.144) on the 5th day but not in OT5 (ps>0.088). There was no significant treatment x genotype interaction for rs53576 (arousal: F2,105= 1.28, p = 0.283, η²p = 0.02, intensity: F2, 105= 0.52, p = 0.599, η²p = 0.01).

However, an exploratory post hoc analysis found that the reductions in arousal and intensity ratings in the OT3 group were only significant in G-non carriers on the 5th day (arousal: p = 0.006 versus PLC, d = 0.87, 95% CI, -1.980 to -0.348; p = 0.012 versus OT5, d = 0.84, 95% CI, -2.102 to 0.265; intensity: p = 0.008 versus PLC, d = 0.72, 95% CI, -1.810 to -0.285; p = 0.193 versus OT5) (Fig. 6).

Since comparable patterns of OT effects were observed on pre- and post-task resting state data right amygdala-vmPFC functional connectivity values were pooled to increase power (Fig. 4B). However, no significant main or interaction effects of genotype for either SNP (rs 2254298 all ps > 0.262; rs53576 all ps > 0.396) were found.

**Discussion**

Overall, our findings firstly validate the use of OT-reductions in amygdala responses to fear-faces and associated emotional intensity and arousal ratings together with
increased resting state functional connectivity between the amygdala and vmPFC as robust markers for its putative therapeutic mechanisms of action. Intriguingly, these task-dependent and resting-state effects of OT show a markedly different sensitivity to repeated intranasal doses and OXTR genotype, although our results indicate that to achieve both maximal task and resting-state changes an optimal protocol using the standard 24IU dose may be to administer it every other day rather than daily. Indeed, both amygdala and behavioral anxiolytic responses to fearful faces were even more pronounced after 5 days when OT was administered every other day and with resting-state functional connectivity changes there was no advantage in terms of their magnitude when OT was administered daily as opposed to every other day.

Our findings are therefore highly consistent with preclinical animal models demonstrating OXTR desensitization following repeated doses of OT in some brain regions (Terenzi and Ingram, 2005; Smith et al., 2005; Stoop, 2012) and that chronic administration can reduce brain OXTR expression (Du et al., 2017) and alter patterns of neurochemical release (Benner et al., 2018). Importantly, chronic doses of OT in rodents fail to produce anxiolytic effects normally seen with single doses (Du et al., 2017) which mirrors our present observations and suggests a translational mechanism of high clinical relevance. The apparent long-lasting desensitization effects of daily OT administration may be contributed to by the magnitude of the doses being administered and if so it is possible that lower daily doses might produce reduced effects.
The amygdala is one of the main neural substrates mediating OT’s functional effects and its attenuation of fear of reactivity in this region is considered as a core therapeutic mechanism of action (Jurek and Neumann, 2018, 2018; Kendrick et al., 2017). Importantly, we have additionally demonstrated that the magnitude of amygdala responses to fear faces are positively associated with intensity and arousal ratings in the PLC group and that OT exerts an anxiolytic action by reducing both these ratings and abolishing their correlation with amygdala activation.

Dysregulations in amygdala and behavioral responses to fear stimuli have been observed across major psychiatric disorders, particularly those characterized by marked social impairments and anxiety (Hennessey et al., 2018; Neumann and Slattery, 2016). Furthermore, our finding that both neural and behavioral anxiolytic effects of OT are stronger after repeated compared to single doses in the group receiving OT every other day supports the assumption that optimal therapeutic effects should be obtained following chronic treatment.

Our second major finding is that OT’s attenuations of neural and behavioral responses to fear faces are highly dependent on OXTR genotype. Only G-non-carriers of rs53576 (i.e. AA) and A-carriers of rs2254298 (i.e. AA and AG) and AA homozygotes for rs53576 and A+ carriers of rs2254298 were significantly responsive to OT. A-carriers of both SNPs have frequently, although not universally, been associated with social dysfunction in autism as well as social anxiety (Cataldo et al., 2018; Jurek and Neumann, 2018). A recent haplotype-based analysis of OXTR SNPs
including rs53576 and rs2254298 also indicated that individually they have some
association with sensitivity to OT-effects on face recognition (Chen et al., 2015).

While the current study clearly indicates that OT modulation of amygdala and visual
cortex responses to fear are strongly associated with the AA genotype (Cohen’s $d_s$
from 0.81-1.41), it remains to be seen whether other OT-dependent effects exhibit the
same association. Limitations to the current findings are that subject numbers are still
relatively low for establishing robust genetic associations and that the AA allele of
rs53576 occurs more frequently in Asian compared with Caucasian populations
(Butovskaya et al., 2016). Also, rs53576 exhibits some sex-dependent differences in
social cooperation effects of OT (Feng et al., 2015b) and our current study focused
only on males to avoid potential menstrual cycle effect issues.

Interestingly, task-related and intrinsic network changes produced by OT showed
a strikingly different sensitivity to repeated doses and OXTR genotype. However,
importantly on the fifth day of treatment there was no advantage of giving OT daily as
opposed to every other day. Intrinsic networks may be less influenced by repeated
doses of OT or OXTR genotype than those activated by tasks, although arguably in
the context of OT’s putative therapeutic effects its task-dependent impact of neural
circuitry engaged during social interactions should be of greatest importance. Future
studies should measure differential OT effects on both task-related and intrinsic
networks.
In conclusion, the current study provides the first evidence for an important influence of dose frequency and receptor genotype on the neural and behavioral actions of intranasal OT in response to fear faces in healthy human subjects. Dose frequency therefore requires further empirical evaluation in patient populations given that it can critically determine treatment efficacy in clinical trials employing chronic administration as an intervention in psychiatric disorders.

Material and Methods

Study design

The main objectives of the study were to firstly investigate the effects of acute (single dose) and repeated doses (daily or every other day for 5 days) of 24IU OT versus PLC on two biomarkers: (1) amygdala and behavioral responses to fearful faces and (2) resting state functional connectivity between the amygdala and mPFC. Secondly we investigated modulatory influences of OXTR rs53576 and rs2254298 polymorphisms on sensitivity to intranasal OT.

Participants. A total of 147 healthy, right-handed healthy adult male subjects were enrolled according to common inclusion and exclusion criteria for human OT-administration studies. This subject number was determine a priori based on achieving 85% power for an expected medium effect size of 0.5. A total of 9 subjects were excluded due to failure to complete the study or excessive head movement (see Fig 1). Subjects were randomly assigned to repeated intranasal treatment (single daily dose on five consecutive days) of (1) placebo (PLC; n = 46, M ± SD, 22.46± 2.3
years), (2) oxytocin (OT5; n = 49, M ± SD, 21.78 ± 2.3 years), or interleaved OT and PLC (OT on days 1, 3, 5, PLC on days 2, 4; OT3; n = 43, M ± SD, 21.02 ± 2.0 years)

(see SI). To ensure compliance all subjects were required to come to the center every day and supervised during self-administration of nasal sprays. To control for between-group differences in potential confounders pre-treatment levels of anxiety, depression, and empathy and trait autism were assessed using validated scales. There were no significant differences between the OT and PLC groups (Table S4). The study was approved by the local ethics committee (Institutional Review Board, University of Electronic Science and Technology of China) and subjects provided written informed consent. The study was in accordance with the latest revision of the Declaration of Helsinki, pre-registered at Clinical Trials.gov (NCT03610919 - https://clinicaltrials.gov/ct2/show/NCT03610919) and in line with recommendations for trials in psychological experiments (Guidi et al., 2018) (see Fig. 1 for Consort flow diagram). Subjects received monetary compensation for participation.

Experimental procedures.

The study employed a double-blind, randomized, placebo-controlled, between-subject design. The OT and PLC sprays used in the 3 groups were both supplied by Sichuan Meike Pharmaceutical Co. Ltd, Sichuan, China in identical dispenser bottles containing identical ingredients (glycerine and sodium chloride) other than OT. In line with recommended guidelines experiments started 45 minutes after intranasal administration (Guastella et al., 2013). In post-treatment interviews collected on days
1 and 5 subjects were unable to identify better than chance whether they had received OT or PLC ($\chi^2 < 0.1$, ps > 0.2, Table S5) confirming successful blinding over the entire study period. For OXTR genotyping subjects provided buccal swaps on the 1st day for analysis of OXTR rs2254298, rs53576 SNPs (see SI and (Montag et al., 2017)).

For the implicit face-emotion processing task 208 grayscale facial stimuli displaying happy, neutral, angry or fearful facial expressions (n = 26 per category, 50% female) were used. Stimuli were initially rated with respect to arousal and valence by an independent group of subjects and two matched independent sets of stimuli were produced for use on the 1st and 5th days (all ps > 0.3, see SI for details and Table S6). The presentation order of the two sets was counter balanced. To ensure attentive processing subjects were required to identify the gender of each face picture (see Figure S2).

**Primary outcomes and analysis plan.**

Face emotion-related amygdala responses were assessed using the event-related implicit face processing fMRI paradigm on treatment days 1 and 5. Intrinsic amygdala connectivity was assessed by means of two resting state fMRI assessments (before and after the task-paradigm). Valence, arousal and intensity ratings (scale: 1-9) for the facial stimuli were collected immediately after MRI acquisition as additional behavioral outcomes (further details see SI). In line with the main aim of the study changes in amygdala fear reactivity and amygdala intrinsic connectivity between the
1\textsuperscript{st} and 5\textsuperscript{th} day served as primary outcome measures. Changes in valence, arousal and intensity ratings for the fear faces represented an associated behavioral outcome measure.

**Imaging acquisition and analysis.**

MRI data was acquired using standard sequences on a 3T GE MR750 system. In addition to the functional time series high resolution T1-weighted structural MRI data was acquired at both time points to improve normalization and control for acute and chronic effects of treatment on brain structure. MRI data was preprocessed using validated procedures in SPM12 (Friston et al., 1994) (Statistical Parametric Mapping; http://www.fil.ion.ucl.ac.uk/spm) and Data Processing Assistant or Resting-State fMRI (Yan, 2010) (DPARSFA; http://rfmri.org/DPARSF) (for details see SI). First level General Linear Models (GLM) for the task-related fMRI data included separate regressors for the four emotional conditions, gender identity rating period and 6 movement parameters and appropriate contrasts were subjected to a second level random effects analysis.

**Statistical analyses**

To identify OT-sensitive regions and confirm previous findings on suppression of amygdala reactivity following single-dose OT-administration (Young and Barrett, 2015) a voxel-wise whole-brain two-sample t-test was conducted in SPM comparing neural activity in OT- and PLC-treated subjects on the 1\textsuperscript{st} day. For all subsequent analyses a 6-mm sphere centered at the maximum t-values of the acute OT effects in
the amygdala served as target region to determine different trajectories of amygdala functioning following acute versus repeated treatment (for similar approach see (Spengler et al., 2017)).

**Primary outcomes: amygdala and behavioral fear-face reactivity and intrinsic connectivity.**

Differences in stimulus-induced amygdala and behavioral responses to fear faces were examined by means of mixed ANOVAs with treatment (PLC, OT$_3$, OT$_5$) as between-subject factor, time point (1$^{st}$ day, acute effects; 5$^{th}$ day, chronic effects) as within-subject factor. Dependent variables were extracted target region amygdala-reactivity towards (parameter estimates extracted using Marsbar, http://marsbar.sourceforge.net) and subsequent valence, intensity and arousal ratings of fearful faces. Bonferroni-corrected post-hoc comparisons were used to explore significant interactions. Associations between amygdala activation in response to fear faces and subsequent behavioral ratings of their valence, intensity and arousal were assessed using Pearson correlation and group differences calculated using Fishers-z tests.

Differences in resting state amygdala functional connectivity were determined using a voxel-wise seed-to-whole-brain ANOVA as implemented in the SPM flexible factorial design with treatment (PLC, OT$_3$, OT$_5$) as between-subject factor, time point (1$^{st}$ day, acute effects; 5$^{th}$ day, chronic effects) as within-subject factor and amygdala connectivity maps as dependent variable. To account for potential effects of
task-engagement on intrinsic amygdala connectivity the primary analysis focused on
pre-task resting state maps. A subsequent ROI analysis on the post-task data (focusing
on extracted estimates from a 6mm sphere centered at vmPFC determined by the
pre-task data) served as a replication and further validation.

Secondary outcome measures: influence of OXTR genotype
For rs2254298 subjects were divided into A+ carriers (AA and AG) and A-
non-carriers (GG) and rs53576 into G+ carriers (GG and GA) and G- non-carriers
(AA). To explore effects of genotype as a secondary outcome measure, OXTR group
was included as additional between-subject factor in the corresponding ANOVAs and
amygdala fear reactivity, amygdala-vmPFC intrinsic functional connectivity and
behavior rating response served as dependent variables.

Control for treatment effects on brain structure.
To control for potential confounding effects of single- and repeated
OT-administration on brain structure, a voxel-based morphometry (VBM) analysis
was conducted on the T1-weighted images acquired on both testing days using
SPM12 standard procedures (Ashburner, 2007; Ashburner and Friston, 2005). Effects
of single- and repeated dose administration were explored concordant with the fMRI
analyses (see SI).

Thresholding and statistical implementation.
Voxel-wise whole brain analyses in SPM were thresholded at a cluster-based Family-wise error (FWE) corrected level ($p < .05$) with an initial cluster forming threshold of $p < .001$ (in line with recent recommendations (Eklund et al., 2016; Mueller et al., 2017)). Behavioral and neural (extracted parameter estimates) indices were analyzed using SPSS 22.0 and appropriate ANOVA models. Partial eta squared ($\eta^2_p$) and Cohen’s $d$ were computed as measures of effect size. Group differences in parameter estimates extracted from significant main effect in SPM were further evaluated using two-sample t tests. All reported $p$ values were Bonferroni-corrected, two-tailed, and $p \leq 0.05$ considered significant.

Acknowledgement: We thank the reviewers and editor for their comments and suggestions for improving the manuscript. Funding: This project was supported by National Natural Science Foundation of Science (NSFC) grant numbers 31530032 (KMK) and 91632117 (BB). Author contributions: JK and KMK designed the experiment. JK, YZ and CS carried out the experiment. JK, KMK, CM, FZ and BB analyzed the experiment and JK, KMK, CM and BB wrote the paper. All authors contributed to the conception of the study and approved the paper. Competing interests: The authors declare that they have no competing interests.
References

Ashburner J. 2013. Symmetric diffeomorphic modeling of longitudinal structural MRI. *Frontiers in Neuroscience* 6. doi:10.3389/fnins.2012.00197

Ashburner J. 2007. A fast diffeomorphic image registration algorithm. *NeuroImage* 38:95–113. doi:10.1016/j.neuroimage.2007.07.007

Ashburner J, Friston KJ. 2005. Unified segmentation. *NeuroImage* 26:839–851. doi:10.1016/j.neuroimage.2005.02.018

Bales KL, Perkeybile AM, Conley OG, Lee MH, Guoyes CD, Downing GM, Yun CR, Solomon M, Jacob S, Mendoza SP. 2013. Chronic Intranasal Oxytocin Causes Long-Term Impairments in Partner Preference Formation in Male Prairie Voles. *Biological Psychiatry* 74:180–188. doi:10.1016/j.biopsych.2012.08.025

Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E. n.d. The Autism-Spectrum Quotient (AQ): Evidence from Asperger Syndrome/High-Functioning Autism, Males and Females, Scientists and Mathematicians 13.

Beck AT, Steer RA, Carbin MG. 1988. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. *Clinical Psychology Review* 8:77–100. doi:10.1016/0272-7358(88)90050-5

Benner S, Aoki Y, Watanabe T, Endo N, Abe O, Kuroda M, Kuwabara H, Kawakubo Y, Takao H, Kunimitsu A, Kasai K, Bito H, Kakeyama M, Yamasue H. 2018.
Neurochemical evidence for differential effects of acute and repeated oxytocin administration. *Molecular Psychiatry*. doi:10.1038/s41380-018-0249-4

Brüne M. 2012. Does the oxytocin receptor polymorphism (rs2254298) confer “vulnerability” for psychopathology or “differential susceptibility”? insights from evolution. *BMC Medicine* 10:38. doi:10.1186/1741-7015-10-38

Butovskaya PR, Lazebny OE, Sukhodolskaya EM, Vasiliev VA, Dronova DA, Fedenok JN, Rosa A, Peletskaya EN, Ryskov AP, Butovskaya ML. 2016. Polymorphisms of two loci at the oxytocin receptor gene in populations of Africa, Asia and South Europe. *BMC Genetics* 17. doi:10.1186/s12863-015-0323-8

Cataldo I, Azhari A, Esposito G. 2018. A Review of Oxytocin and Arginine-Vasopressin Receptors and Their Modulation of Autism Spectrum Disorder. *Frontiers in Molecular Neuroscience* 11. doi:10.3389/fnmol.2018.00027

Chen FS, Kumsta R, Dvorak F, Domes G, Yim OS, Ebstein RP, Heinrichs M. 2015. Genetic modulation of oxytocin sensitivity: a pharmacogenetic approach. *Translational Psychiatry* 5:e664–e664. doi:10.1038/tp.2015.163

Du P, He Z, Cai Z, Hao X, Dong N, Yuan W, Hou W, Yang J, Jia R, Tai F. 2017. Chronic central oxytocin infusion impairs sociability in mandarin voles. *Pharmacology Biochemistry and Behavior* 161:38–46. doi:10.1016/j.pbb.2017.09.006
Eckstein M, Becker B, Scheele D, Scholz C, Preckel K, Schlaepfer TE, Grinevich V, Kendrick KM, Maier W, Hurlemann R. 2015. Oxytocin Facilitates the Extinction of Conditioned Fear in Humans. *Biological Psychiatry* 78:194–202. doi:10.1016/j.biopsych.2014.10.015

Eickhoff SB, Stephan KE, Mohlberg H, Grefkes C, Fink GR, Amunts K, Zilles K. 2005. A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. *NeuroImage* 25:1325–1335. doi:10.1016/j.neuroimage.2004.12.034

Eklund A, Nichols TE, Knutsson H. 2016. Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates. *Proceedings of the National Academy of Sciences* 113:7900–7905. doi:10.1073/pnas.1602413113

Feng C, Lori A, Waldman ID, Binder EB, Haroon E, Rilling JK. 2015a. A common oxytocin receptor gene (*OXTR*) polymorphism modulates intranasal oxytocin effects on the neural response to social cooperation in humans: OXTR polymorphism and oxytocin effects. *Genes, Brain and Behavior* 14:516–525. doi:10.1111/gbb.12234

Feng C, Lori A, Waldman ID, Binder EB, Haroon E, Rilling JK. 2015b. A common oxytocin receptor gene (*OXTR*) polymorphism modulates intranasal oxytocin effects on the neural response to social cooperation in humans: OXTR polymorphism and oxytocin effects. *Genes, Brain and Behavior* 14:516–525. doi:10.1111/gbb.12234
Friston KJ, Holmes AP, Worsley KJ, Poline J-P, Frith CD, Frackowiak RSJ. 1994. Statistical parametric maps in functional imaging: A general linear approach. *Human Brain Mapping* 2:189–210. doi:10.1002/hbm.460020402

Guastella AJ, Gray KM, Rinehart NJ, Alvares GA, Tonge BJ, Hickie IB, Keating CM, Cacciotti-Saija C, Einfeld SL. 2015. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. *Journal of Child Psychology and Psychiatry* 56:444–452. doi:10.1111/jcpp.12305

Guastella AJ, Hickie IB, McGuinness MM, Otis M, Woods EA, Disinger HM, Chan H-K, Chen TF, Banati RB. 2013. Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. *Psychoneuroendocrinology* 38:612–625. doi:10.1016/j.psyneuen.2012.11.019

Guidi J, Brakemeier E-L, Bockting CLH, Cosci F, Cuijpers P, Jarrett RB, Linden M, Marks I, Peretti CS, Rafanelli C, Rief W, Schneider S, Schnyder U, Sensky T, Tomba E, Vazquez C, Vieta E, Zipfel S, Wright JH, Fava GA. 2018. Methodological Recommendations for Trials of Psychological Interventions. *Psychotherapy and Psychosomatics* 87:276–284. doi:10.1159/000490574

Halverson T, Jarskog LF, Pedersen C, Penn D. 2019. Effects of oxytocin on empathy, introspective accuracy, and social symptoms in schizophrenia: A 12-week twice-daily randomized controlled trial. *Schizophrenia Research* 204:178–182. doi:10.1016/j.schres.2018.09.013
Hennessey T, Andari E, Rainnie DG. 2018. RDoC-based categorization of amygdala functions and its implications in autism. Neuroscience & Biobehavioral Reviews 90:115–129. doi:10.1016/j.neubiorev.2018.04.007

Huang H, Michetti C, Busnelli M, Managò F, Sannino S, Scheggia D, Giancardo L, Sona D, Murino V, Chini B, Scattoni ML, Papaleo F. 2014. Chronic and Acute Intranasal Oxytocin Produce Divergent Social Effects in Mice. Neuropsychopharmacology 39:1102–1114. doi:10.1038/npp.2013.310

Jarskog LF, Pedersen CA, Johnson JL, Hamer RM, Rau SW, Elliott T, Penn DL. 2017. A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia. Schizophrenia Research 185:88–95. doi:10.1016/j.schres.2017.01.008

Jurek B, Neumann ID. 2018. The Oxytocin Receptor: From Intracellular Signaling to Behavior. Physiological Reviews 98:1805–1908. doi:10.1152/physrev.00031.2017

Kendrick KM, Guastella AJ, Becker B. 2017. Overview of human oxytocin researchBehavioral Pharmacology of Neuropeptides: Oxytocin. Springer. pp. 321–348.

Kvaal K, Ulstein I, Nordhus IH, Engedal K. 2005. The Spielberger State-Trait Anxiety Inventory (STAI): the state scale in detecting mental disorders in geriatric patients. International Journal of Geriatric Psychiatry 20:629–634. doi:10.1002/gps.1330
Lohse MJ, Hofman KP. 2015. Spatial and temporal aspects of signaling by G-protein-coupled receptors. *Molecular Pharmacology* **88**:572-578. doi:10.1124/mol.115.100248

Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. 2011. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. *Nature Reviews Neuroscience* **12**:524–538. doi:10.1038/nrn3044

Montag C, Sindermann C, Melchers M, Jung S, Luo R, Becker B, Xie J, Xu W, Guastella AJ, Kendrick KM. 2017. A functional polymorphism of the **OXTR** gene is associated with autistic traits in Caucasian and Asian populations. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics* **174**:808–816. doi:10.1002/ajmg.b.32596

Mueller K, Lepsien J, Möller HE, Lohmann G. 2017. Commentary: Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates. *Frontiers in Human Neuroscience* **11**. doi:10.3389/fnhum.2017.00345

Neumann ID, Slattery DA. 2016. Oxytocin in General Anxiety and Social Fear: A Translational Approach. *Biological Psychiatry* **79**:213–221. doi:10.1016/j.biopsych.2015.06.004

Parker KJ, Garner JP, Libove RA, Hyde SA, Hornbeak KB, Carson DS, Liao C-P, Phillips JM, Hallmayer JF, Hardan AY. 2014. Plasma oxytocin concentrations and OXTR polymorphisms predict social impairments in children with and without autism spectrum disorder. *Proceedings of the National Academy of Sciences* **111**:12258–12263. doi:10.1073/pnas.1402236111
Pierce KL, Premont RT, Lefkowitz RJ. 2002. Seven-transmembrane receptors. *Nature Reviews Molecular Cell Biology* 3:639-650

Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. 2012. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. *NeuroImage* 59:2142–2154.

doi:10.1016/j.neuroimage.2011.10.018

Russell JA. 2018. 50 years of advances in neuroendocrinology. *Brain and Neuroscience Advances*. 2:1-20. doi:10.1177/2398212818812014

Siu AMH, Shek DTL. 2005. Validation of the Interpersonal Reactivity Index in a Chinese Context. *Research on Social Work Practice* 15:118–126.

doi:10.1177/1049731504270384

Smith MP, Ayad VJ, Mundell SJ, McArdle CA, Kelly E, López Bernal, A. 2006. Internalization and desensitization of the oxytocin receptor is inhibited by dynamin and clathrin mutants in human embryonic kidney 293 cells. *Molecular Endocrinology* 20:379-388. doi:10.1210/me.2005-0031

Spengler FB, Schultz J, Scheele D, Essel M, Maier W, Heinrichs M, Hurlemann R. 2017. Kinetics and Dose Dependency of Intranasal Oxytocin Effects on Amygdala Reactivity. *Biological Psychiatry* 82:885–894.

doi:10.1016/j.biopsych.2017.04.015

Stoop R. 2012. Neuromodulation by Oxytocin and Vasopressin. *Neuron* 76:142–159.

doi:10.1016/j.neuron.2012.09.025
Terenzi MG, Ingram CD. 2005. Oxytocin-induced excitation of neurones in the rat central and medial amygdaloid nuclei. Neuroscience 134:345-354. doi:10.1016/j.neuroscience.2005.04.004

Watanabe T, Kuroda M, Kuwabara H, Aoki Y, Iwashiro N, Tatsunobu N, Takao H, Nippashi Y, Kawakubo Y, Kunimatsu A, Kasai K, Yamasue H. 2015. Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism. Brain 138:3400–3412. doi:10.1093/brain/awv249

Yamasue H, Okada T, Munesue T, Kuroda M, Fujioka T, Uno Y, Matsumoto K, Kuwabara H, Mori D, Okamoto Y, Yoshimura Y, Kawakubo Y, Arioka Y, Kojima M, Yuhi T, Owada K, Yassin W, Kushima I, Benner S, Ogawa N, Eriguchi Y, Kawano N, Uemura Y, Yamamoto M, Kano Y, Kasai K, Higashida H, Ozaki N, Kosaka H. 2018. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial. Molecular Psychiatry. doi:10.1038/s41380-018-0097-2

Yan. 2010. DPARSF: a MATLAB toolbox for “pipeline” data analysis of resting-state fMRI. Frontiers in System Neuroscience. doi:10.3389/fnsys.2010.00013

Yang S, Dong X, Guo X, Han Y, Song H, Gao L, Dai W, Su Y, Zhang X. 2017. Serum Oxytocin Levels and an Oxytocin Receptor Gene Polymorphism (rs2254298) Indicate Social Deficits in Children and Adolescents with Autism Spectrum Disorders. Frontiers in Neuroscience 11. doi:10.3389/fnins.2017.00221
Young LJ, Barrett CE. 2015. Can oxytocin treat autism? Science 347:825–826.

doi:10.1126/science.aaa8120

Zhao W, Becker B, Yao S, Ma X, Kou J, Kendrick KM. 2018. Oxytocin Enhancement of the Placebo Effect May Be a Novel Therapy for Working Memory Impairments. Psychotherapy and Psychosomatics 1–2.

doi:10.1159/000495260

Zhao Z, Yao S, Li K, Sindermann C, Zhou F, Zhao W, Li J, Lührs M, Goebel R, Kendrick KM, Becker B. 2019. Real-Time Functional Connectivity-Informed Neurofeedback of Amygdala-Frontal Pathways Reduces Anxiety. Psychotherapy and Psychosomatics 1–11. doi:10.1159/000496057
Figures:

Fig. 1 CONSORT flow diagram of the clinical trial.
Fig. 2

The effect of intranasal oxytocin (OT) treatment on neural responses to fearful faces on the 1st day. (A) The t-map of the treatment effect (FWE c = 78, t = 3.93, p = 0.043) showed an activated cluster peaking at the right amygdala (x = 27, y = −4, z = −13). (B) Parameter estimates extracted using a 6-mm radius sphere centered at the peak MNI coordinates at the right amygdala on the 1st and 5th day separately revealed that OT treatment on alternate days (OT₃) decreased amygdala responses on both the 1st and 5th days whereas for the daily OT treatment group (OT₅) group the decrease only occurred on the 1st day. * p < 0.05, ** p < 0.01, two-tailed t-test. Bars indicate M ± SE.
Fig. 3 Oxytocin influenced intensity and arousal ratings. Oxytocin decreased intensity and arousal ratings of fearful faces only on the 5th day of treatment in the group receiving OT on alternate days (OT3) compared with placebo (PLC). *p< 0.05. **p<0.01. Bars depict M ± SE.
Fig. 4

 Associations between intensity and arousal ratings of fear faces and amygdala activation in the three treatment groups (PLC, OT3 and OT5) on days 1 and 5. *p < 0.05, **p < 0.01

Fig. 5

vmPFC-Right Amygdala
Fig. 5 The effects of oxytocin (OT) on resting state functional connectivity (A)

schematic showing functional connection between the right amygdala and ventromedial prefrontal cortex (vmPFC). Whole brain functional connectivity (FC) used the right amygdala as a region of interest (6mm sphere, x=27, y=-4, z=-13) and (B) revealed significant increased functional connectivity between vmPFC and right amygdala ($p_{FWE} < 0.05$, x=-3, y=53, z=-19) in both OT treatment groups (every day – OT and every other day - OT on both days 1 and 5). Data for the two resting state periods before and after the face emotion task were similar and are therefore showed here combined. Bar graph illustrates the extraction of parameter estimates from right amygdala connectivity with vmPFC ($M \pm SE$). * $p < 0.05$, ** $p < 0.01$, two-tailed t-test. Bars indicate $M \pm SE$. 

675 676 677 678 679 680 681 682 683 684 685 686 687
Fig.6 Influence of oxytocin receptor genotype on right amygdala responses to fearful faces (n = 111 subjects). (A)-(B): for rs 53576 only G-non carriers (i.e. AA) showed reduced amygdala response to fearful faces and for rs2254298 only A-carriers (i.e. AA and AG) in the groups with intranasal oxytocin treatment either daily (OT) or
every other day (OT). (C)-(D): A similar pattern was found for rs2254298, but not rs53576 for arousal ratings of fearful faces although only on day 5 in the OT group. 

(E)-(F): A similar pattern was found for rs2254298, but not rs53576 for intensity ratings of fearful faces although only on day 5 in the OT group ** p < 0.005, * p < 0.0125, two-tailed t-test (Bonferroni corrected significance threshold of p = 0.0125).

Bars indicate M ± SE.
Supplementary information for

Kou et al., “Genotype and dose-frequency may critically determine the therapeutic efficacy of chronic oxytocin treatment”

Supplementary Methods

Supplementary Results

Supplementary Tables

Supplementary Figures
Supplementary Methods

Participants

147 healthy, right-handed healthy adult subjects were recruited by local advertisement. All subjects had normal or corrected to normal vision and no history of or current neurological or psychiatric disorders. Participants were free from current (one month before the experiment) or regular use of medication and were required to abstain from caffeine, alcohol and tobacco at least 24 hours before the experiment. Four subjects were not able to attend all study appointments and 5 were excluded due to head movement during the fMRI assessment (motion > 3.0mm translation or 3° and mean frame-wise displacement (FD < 0.5 mm) (Power et al., 2012), Pre-treatment levels of anxiety, depression, trait autism and empathy were assessed using validated scales (State-Trait Anxiety Inventory (STAI) (Kvaal et al., 2005), Beck Depression Inventory (Beck et al., 1988), Autism-Spectrum Quotient (AQ) (Baron-Cohen et al., n.d.), and Interpersonal Reactivity Index (IRI) (Siu and Shek, 2005).

Stimuli and face task

208 gray scaled facial stimuli displaying happy, neutral, angry or fearful facial expressions (n = 26 per category, 50% female) were used employed for the implicit emotional face processing task. Stimuli were initially rated with respect to arousal and valence by an independent group of participants (n = 24 participants, 10 females, age, M ± SD, 21.3 ± 1.9 years). Based on these valence and arousal ratings two independent sets of stimuli for the 1st day and 5th day were constructed with matched
arousal and valence (all ps > 0.3, see Table S6) and the order of the two sets are counter balanced in the treatment group and control group.

Subjects were instructed to attentively process the presented facial stimuli and were required to indicate the gender of the actor after presentation (left button press for male, right button press for female face) to ensure attentive processing. Stimuli were presented for 3s followed by a jittered fixation (1.5-2.1s) followed by the gender discrimination task presented for 2s (2s) and followed by a jittered inter-trial interval (4.5-6s) that served as low level baseline. Order of gender and emotion was pseudo-randomized (see also Fig. S2).

Imaging acquisition of fMRI data

fMRI data employing blood oxygenation level-dependent (BOLD) contrast was acquired on a 3T GE MR750 system. Functional images for task-based and resting state data assessments were acquired using EPI sequences (TR=2000ms, echo time=30ms, flip angle=90°, FOV=240mm × 240mm, voxel size= 3.75 × 3.75 ×4 mm, resolution=64 × 64, the number of slices=39). T1-weighted anatomical images were additionally acquired to improve normalization of the functional images and additionally served to explore structural changes related to OT treatment (TR=6ms, echo time=2ms, flip angle=9°, FOV=256mm × 256mm, voxel size =1×1×1mm, number of slices=156).

fMRI data preprocessing (Implicit emotional face processing task part)
Task-related fMRI data analyzed using SPM12 (Friston et al., 1994) (Statistical Parametric Mapping; http://www.fil.ion.ucl.ac.uk/spm). The first 5 volumes were discarded to allow T1 equilibration and the remaining images were applied to correct for temporal slice acquisition differences and then realigned and unwarped to correct for head motion (six-parameter rigid body algorithm), and slice-timing correction. Tissue segmentation, bias-correction were applied to the high-resolution structural images. After co-registration of the functional time-series with the skull-stripped anatomical scan the transformation matrix was applied to normalized the functional images to MNI space with a voxel size of 3 × 3 × 3 mm. Normalized images were spatially smoothed using a Gaussian kernel with full-width at half-maximum (FWHM) of 5 mm. Participants with head motion exceeding 3.0 mm translation or 3° rotation and mean frame-wise displacement (FD > 0.5 mm) were excluded. Mean frame-wise displacement (FD) were controlled between OT treatment group and PLC control group (see Table S7).

fMRI data preprocessing (resting state)

Resting state data was analyzed using SPM12 (Statistical Parametric Mapping; http://www.fil.ion.ucl.ac.uk/spm) and Data Processing Assistant for Resting-State fMRI (Yan, 2010) (DPARSFA; http://rfmri.org/DPARSF). After discarding the first 5 scans, preprocessing included slice-time correction, head motion correction using six-parameter rigid body algorithm. Then they were co-registered with the anatomical scan and normalized to MNI space with voxel size of 3 × 3 × 3 mm. Normalized
images were then spatially smoothed using a Gaussian kernel with full-width at half-maximum (FWHM) of 5mm. As for nuisance signal correction, the following nuisance parameters were included as regressors, 6 head motion parameters, 6 head motion parameters one time point before, and their squares, white matter (WM) and cerebrospinal fluid (CSF). After filtering with the band of (0.01-0.1HZ) and linear detrending, the functional connectivity of data has been calculated on the whole brain level based on the region of activation during task. Participants with head motion exceeding 3.0mm translation or 3° rotation and mean frame-wise displacement (FD > 0.5 mm) were excluded. Mean frame-wise displacement (FD) were controlled between OT treatment and PLC control groups (see Table S7).

fMRI data preprocessing (voxel-based morphometry part)

To further control for potential confounding effects of single- and repeated dose administration of OT on brain structure a voxel-based morphometry (VBM) analysis was performed on the T1-weighted images acquired on both testing days. Processing for longitudinal effects included unified segmentation, DARTEL preprocessing, and Pairwise Longitudinal Registration (Ashburner, 2013) using in SPM12 according to standard procedures(Ashburner, 2007; Ashburner and Friston, 2005). Repeated administration effects on gray matter (GM) were assessed using whole-brain analysis across groups. For the acute effect identical preprocessing was applied without the longitudinal registration step including T1 images from the 1st day and an independent samples t test to compare OT and PLC treated participants.
Genotyping

A total of 120 subjects (samples could not be analyzed from 27 subjects either due to problems with buccal cell sampling or equivocal genotyping results) were successfully genotyped from buccal cell swabs. DNA was extracted by a MagNa Pure 96 robot (Roche Diagnostics, Mannheim, Germany) with a commercial Viral NA Small Volume Kit (Roche Diagnostics, Mannheim, Germany). Polymorphisms were analyzed by means of a real time quantitative polymerase chain reaction (PCR) and subsequent high resolution melting detection analysis with a LightCycler Cobas z480 (Roche Diagnostics, Mannheim, Germany). Simple probe assay designs provided by TibMolBiol (Berlin, Germany) were conducted. The following SNPs were investigated for participants in the present study: OXTR rs2254298, rs53576 (see Tables S2 and S3 for distribution and Hardy Weinberg details).

Supplementary Results

Bilateral calcarine cortex responses to fear faces and associations with OXTR genotype

Mixed ANOVAs with treatment (PLC, OT₃, OT₅) and time point (1ˢᵗ day, acute effects; 5ˢᵗ day, chronic effects) as factors revealed a significant main effect of treatment ($F_{2, 135} = 11.52$, $p < 0.001$, $\eta^2_p = 0.146$) and treatment x time point interaction ($F_{2, 135} = 3.22$, $p = 0.043$, $\eta^2_p = 0.046$). Post hoc comparisons confirmed that OT significantly decreased calcarine cortex responses in the OT₃ ($p < 0.001$, $d = 0.97$) and OT₅ ($p < 0.001$, $d = 0.72$) groups relative to PLC on the 1ˢᵗ day. No differences were observed between the OT-treatment groups on the 1ˢᵗ day ($p = 0.351$, $d = 0.21$).
the 5th day, suppression of calcarine cortex fear reactivity relative to the PLC-group
was maintained in the OT3 (p < 0.001, d = 0.81) but not the OT5 group (p = 0.326, d =
0.19) and the OT3 group was also significantly different from the OT5 group (p =
0.006, d = 0.62). Thus, the bilateral calcarine cortex showed similar evidence to the
right amygdala for a reduced effect of OT with daily repeated doses after 5 days.

For calcarine cortex responses there was a significant treatment x genotype
interaction for rs53576 (F_{2, 105}= 5.17, p = 0.007, \eta^2_p = 0.09) although for rs2254298 it
did not reach significance (F_{2, 105}= 2.18, p = 0.118, \eta^2_p = 0.04). For rs53576,
OT-induced suppression on day 1 was only significant in G-non-carriers (AA - p < 0.001, Cohen’s d =1.12) and also on the 5th day in the OT3 group (AA - p < 0.001,
Cohen’s d =1.28) and OT5 group (p = 0.006, Cohen’s d =0.92). An exploratory post
hoc analysis for rs2254298 revealed that OT-induced suppression on the 1st day across
treatment groups was only significant in A-carriers (AA and AG- p < 0.001, Cohen’s
d =1.20) and also on the 5th day in the OT3 group (AA and AG - p < 0.001, Cohen’s d
=1.24). Thus the calcarine cortex showed a similar pattern of receptor genotype
dependency for the effects of OT as the amygdala.

**Bilateral calcarine cortex responses to fear faces and associations with intensity
and arousal ratings**

Associations between calcarine (visual) cortex responses to fear faces and arousal and
intensity ratings were marginal in the PLC group on the 1st day (arousal: r = 0.28, p =
0.059; intensity: r = 0.22, p = 0.150) and were not influenced by OT (arousal: OT3, r =
0.15 p = 0.329; Fisher’s z = 0.31, p = 0.540; OT5, r = 0.08, p = 0.584; z = 0.98, p =
0.328; intensity: OT3, r = 0.24, p = 0.123; Fisher’s z = 0.11, p = 0.912; OT5, r = 0.12,
p = 0.423; z = 0.18, p = 0.859). However, on the 5th day there was a significant
association for arousal ratings in the PLC group (PLC: r = 0.35 p = 0.016) and this
was significantly reduced in the OT₃ group (r = -0.10 p = 0.544; z = 2.12, p = 0.034) but not the OT₅ group (r = 0.05 p = 0.725; z = 1.50, p = 0.134). Intensity ratings on the 5th day showed a similar pattern (PLC: r = 0.37 p = 0.012; OT₃, r = -0.05 p = 0.734; z = 1.98, p = 0.047; OT₅ group, r = 0.108 p = 0.462; z = 1.29, p = 0.195) (Fig.S4).

**Superior frontal gyrus responses to fear faces and associations with OXTR genotype**

Mixed ANOVAs with treatment (PLC, OT₃, OT₅) and time point (1st day, acute effects; 5th day, chronic effects) as factors revealed a significant main effect of treatment (F₍2, 135₎ = 6.80, p = 0.002, $\eta_p^2$ = 0.092) but no treatment x time point interaction (F₍2, 135₎ = 0.55, p = 0.576, $\eta_p^2$ = 0.008). Exploratory post hoc comparisons confirmed that OT significantly decreased superior frontal gyrus responses in the OT₃ (p = 0.005, d = 0.59) and OT₅ (p = 0.001, d = 0.67) groups relative to PLC on the 1st day. No differences between the OT-treatment groups were observed on the 1st day (p = 0.753, d = 0.06). On the 5th day, suppression of superior frontal gyrus fear reactivity relative to the PLC-group was maintained in the OT₃ group (p = 0.011, d = 0.63) and the OT₅ group (p = 0.045, d = 0.38). No differences between the OT-treatment groups were observed on the 5th day (p = 0.528, d = 0.13). Thus, there was no evidence for reduced superior frontal gyrus responses to daily OT doses being reduced after 5 days.

For superior frontal gyrus responses there was no significant treatment x genotype interaction for rs53576 (F₍2, 105₎ = 1.19, p = 0.309, $\eta_p^2$ = 0.02) or for rs2254298
(F2, 105= 1.28, p = 0.279, η²p = 0.02) indicating that there was no significant influence of OXTR genotype on responses.

Superior frontal gyrus responses to fear faces and associations with arousal and intensity ratings

There were no significant associations between superior frontal gyrus responses to fear faces and arousal and intensity ratings for PLC or OT groups on the 1st or 5th days (ps > 0.11) (Fig.S5).

Neural and behavioral responses to fearful faces in association with combined rs53576 and rs2254298 genotypes

We also carried out an exploratory analysis of neural responses and intensity ratings for fearful faces for the 4 different combined rs53576 and rs2254298 genotypes following acute OT treatment (i.e. using combined OT3 and OT5 groups on the 1st day versus PLC to increase power). The 4 different combined genotypes had an approximately equal distribution (see Fig. S3). For right amygdala responses, there was a marginal significant treatment x genotype interaction for combined genotype of rs53576 and rs2254298 (F2, 110= 2.20, p = 0.093, η²p = 0.06). Post hoc analysis indicated OT-induced suppression on day 1 was significant in the group with both G-non-carriers of rs53576 (i.e. AA) and A-carriers of rs2254298 (i.e. AA or AG - p < 0.001, Cohen’s d =1.25) (see Fig. S3).
For the bilateral calcarine cortex response to fearful faces, the treatment x genotype interaction for the combined genotype of rs53576 and rs2254298 was marginally significant ($F_{2, 110} = 2.10$, $p = 0.105$, $\eta^2_p = 0.06$). Again an exploratory post hoc analysis indicated OT-induced suppression on the 1st day was significant in the group with both G-non-carriers of rs53576 (AA) and A-carriers of rs2254298 (AA or AG - $p = 0.001$, Cohen’s $d = 1.26$), similar to the pattern in right amygdala (see Fig. S3).

For the superior frontal gyrus responses there was no treatment x genotype interaction for the combined genotype of rs53576 and rs2254298 ($F_{2, 110} = 0.09$, $p = 0.96$, $\eta^2_p = 0.003$) and no significant exploratory post-hoc findings.

For intensity ratings of fearful faces there was a marginal treatment x genotype interaction for the combined genotype of rs53576 and rs2254298 ($F_{2, 110} = 2.35$, $p = 0.08$, $\eta^2_p = 0.009$) and an exploratory post-hoc analysis showed that OT-induced reductions in intensity ratings on the 1st day were significant in the group with both G-non-carriers of rs53576 (AA) and A-carriers of rs2254298 (AA or AG - $p = 0.009$, Cohen’s $d = 0.85$). For arousal ratings for fearful faces there was no significant treatment x genotype interaction for the combined genotype of rs53576 and rs2254298 ($F_{2, 110} = 1.92$, $p = 0.13$, $\eta^2_p = 0.053$) but an exploratory post-hoc analysis showed that OT-induced reduction in intensity ratings on the 1st day was marginally significant (after correction) in the group with both G-non-carriers of rs53576 (AA) and A-carriers of rs2254298 (AA or AG - $p = 0.020$, Cohen’s d=0.75) (see Fig. S3).
Table S1  Whole brain acute effect (1st day) of intranasal OT on neural responses to fearful faces

| Regions                | x   | y   | z   | k  | P_{FWE} |
|------------------------|-----|-----|-----|----|---------|
| OT<PLC (fear faces)    |     |     |     |    |         |
| Calcarine_R (aal)      | 18  | -82 | 8   | 156| 0.002   |
| Calcarine_L (aal)      | 0   | -88 | 5   |    |         |
| Occipital_Sup_R (aal)  | 18  | -91 | 20  |    |         |
| Frontal_Mid_R (aal)    | 27  | 8   | 56  | 82 | 0.036   |
| Frontal_Sup_R (aal)    | 33  | -4  | 59  |    |         |
| Frontal_Sup_L (aal)    | 21  | -1  | 52  |    |         |
| Amygdala_R (aal)       | 27  | -4  | -13 | 78 | 0.043   |
| Putamen_R (aal)        | 30  | 5   | -7  |    |         |

Table S2  The number of A carriers (A+) and A non-carriers (A-) of rs2254298, G carriers (G+) and G non-carriers (G-) of rs53576 in each treatment group

| Genotypes   | PLC | OT3 | OT5 | In total | χ²   | P       | η²   |
|-------------|-----|-----|-----|----------|------|---------|------|
| rs2254298(A+) | 20  | 23  | 20  | 63       | 0.088| 0.957   | 0.025|
| rs2254298(A-) | 16  | 18  | 14  | 48       | 2.824| 0.244   | 0.124|
Table S3 Distribution of Genotypes in the Sample of N=120 participants

| Genotypes | HWE                  |
|-----------|----------------------|
| rs2254298 |                      |
| AA: 15    | AG: 53               |
| GG: 52    | Total: 120           |
| Chi² = 0.07, p = .794 |

| rs53576   |                      |
| AA: 60    | AG: 45               |
| GG: 15    | Total: 120           |
| Chi² = 1.94, p = .163 |

Table S4 Pre-treatment anxiety, depression, autism and empathy scores in both groups

| Questionnaire | PLC         | OT₁            | OT₂            | F    | P    |
|---------------|-------------|----------------|----------------|------|------|
| STAI, state   | 38.78±11.53 | 35.49±10.69    | 37.14±8.92     | 1.13 | 0.33 |
| STAI, trait   | 41.67±11.60 | 40.28±10.51    | 39.20±8.94     | 0.81 | 0.15 |
| BDI           | 9.84±9.13   | 8.93±8.08      | 8.00±7.45      | 0.57 | 0.57 |
| AQ            | 20.91±5.57  | 20.35±5.91     | 19.47±4.57     | 0.88 | 0.42 |
| IRI           | 50.59±9.84  | 53.02±8.74     | 49.39±9.81     | 1.72 | 0.18 |
Table S5 Chi Squared Test of post-experiment interviews where subjects were required to identify which treatment they received. In all cases subjects were unable to guess better than chance.

| Day | PLC | OT3 | OT5 | In total | χ²  | P     | η²  |
|-----|-----|-----|-----|----------|-----|-------|-----|
| 1   | 24  | 20  | 22  | 66       | 0.547 | 0.76 | 0.062 |
| 2   | 20  | 15  | 17  | 52       | 0.988 | 0.61 | 0.078 |
| 3   | 24  | 28  | 24  | 76       | 2.645 | 0.27 | 0.014 |
| 4   | 19  | 28  | 20  | 57       | 0.01  | 0.99 | 0.003 |
| 5   | 25  | 25  | 24  | 74       | 0.787 | 0.68 | 0.039 |

Table S6 Ratings for each of the two sets of different face emotion stimuli used on the 1st day and 5th day in a counterbalanced design. There were no significant differences between the two sets for valence and arousal ratings.

|        | Valence | Arousal |
|--------|---------|---------|
|        | Set A On the 1st day | Set B On the 5th day | t  | p   | Set A On the 1st day | Set B On the 5th day | t  | p   |
| Happy  | 6.26±0.94 | 6.25±0.97 | 0.04 | 0.97 | 5.50±0.59 | 5.52±0.44 | 0.12 | 0.90 |
| Neutral| 5.67±0.17 | 5.61±0.16 | 1.06 | 0.30 | 3.03±0.36 | 2.98±0.32 | 0.55 | 0.59 |
| Fear   | 6.40±1.02 | 6.31±0.17 | 0.34 | 0.74 | 6.71±0.70 | 6.70±0.63 | 0.03 | 0.98 |
| Angry  | 6.16±0.98 | 6.04±1.04 | 0.48 | 0.64 | 5.66±0.84 | 5.83±0.99 | 0.82 | 0.42 |
**Table S7** Group Comparison of Mean frame-wise displacement

| fMRI tasks               | t \(_{OT3 VS PLC}\) | P \(_{OT3 VS PLC}\) | t \(_{OT5 VS PLC}\) | P \(_{OT5 VS PLC}\) |
|--------------------------|---------------------|---------------------|---------------------|---------------------|
| Day1-Face task           | 0.588               | 0.558               | 0.261               | 0.795               |
| Day5-Face task           | 1.056               | 0.294               | 0.097               | 0.925               |
| Day1-rs-fMRI-1           | 1.841               | 0.069               | 1.025               | 0.308               |
| Day1-rs-fMRI-2           | 0.569               | 0.571               | 0.763               | 0.448               |
| Day5-rs-fMRI-1           | 0.739               | 0.462               | 1.305               | 0.193               |
| Day5-rs-fMRI-2           | 0.676               | 0.501               | 1.216               | 0.227               |

**Fig. S1.** Treatment protocol. Participants were randomly assigned to have nasal spray of oxytocin (OT) for 5 days 24 IU per day (OT\(_3\) group) or have OT or placebo nasal spray on alternate days during the 5 days (OT on the 1\(^{st}\), 3\(^{rd}\) and 5\(^{th}\) day), 24 IU per day (OT\(_3\) group) or have daily nasal spray of PLC for 5 days (PLC group).
Fig.S2 Face emotion task procedure. Face stimuli appeared on the screen for 3 seconds, and then on the subsequent response screen participants were required to press the left or right response key to identify the gender of the face they had seen.
Fig.S3 The influence of combined rs53576 and rs2254298 genotypes on oxytocin acute treatment effect on brain activation and behavioral response (A) right amygdala and (B) bilateral calcarine gyrus responses to fear faces in the placebo (PLC) and combined oxytocin (OT) treatment groups on the 1st treatment day and (C) the same for arousal ratings (D) and intensity ratings of fear faces. ** p < 0.001 and # p < 0.05. After Bonferroni correction p < 0.0125 considered significant. Subject numbers for combined rs 2254298 and rs 53576: A+ & G- 13 (PLC), 24 (OT); A- & G+ 8 (PLC), 18 (OT); A- & G- 8 (PLC), 14 (OT); A+ & G+ 7 (PLC), 19 (OT).
Fig. S4  
Associations between calcarine cortex (visual cortex) responses to fear faces and arousal and intensity ratings in the three treatment groups (PLC, OT_3 and OT_5). * p < 0.05. # p< 0.1.
Fig. S5 Associations between superior frontal gyrus responses to fear faces and arousal and intensity ratings in the three treatment groups (PLC, OT3 and OT5). * p < 0.05